Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0004 0.00 (0.00%)
As of 06/12/2026 12:55 PM Eastern
Compare

TTOO vs. SDCCQ, GMVDF, VRAYQ, AFIB, and UTRS

Should you buy T2 Biosystems stock or one of its competitors? MarketBeat compares T2 Biosystems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with T2 Biosystems include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does T2 Biosystems compare to SmileDirectClub?

T2 Biosystems (NASDAQ:TTOO) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

T2 Biosystems has a beta of 7.8, meaning that its share price is 680% more volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
SmileDirectClub N/A N/A N/A

T2 Biosystems has higher earnings, but lower revenue than SmileDirectClub. T2 Biosystems is trading at a lower price-to-earnings ratio than SmileDirectClub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A

23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 64.7% of SmileDirectClub shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, T2 Biosystems had 1 more articles in the media than SmileDirectClub. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for SmileDirectClub. T2 Biosystems' average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
SmileDirectClub Neutral

Summary

T2 Biosystems and SmileDirectClub tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

G Medical Innovations has a beta of 27.28, indicating that its share price is 2,628% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.8, indicating that its share price is 680% more volatile than the broader market.

G Medical Innovations has higher earnings, but lower revenue than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.00-$24.63MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

In the previous week, T2 Biosystems had 1 more articles in the media than G Medical Innovations. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for G Medical Innovations. G Medical Innovations' average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
G Medical Innovations Neutral
T2 Biosystems Neutral

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Summary

G Medical Innovations beats T2 Biosystems on 5 of the 8 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, T2 Biosystems had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for ViewRay. ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Neutral

ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.8, meaning that its share price is 680% more volatile than the broader market.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

T2 Biosystems has lower revenue, but higher earnings than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ViewRay and T2 Biosystems tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, T2 Biosystems had 1 more articles in the media than Acutus Medical. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for Acutus Medical. Acutus Medical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
T2 Biosystems Neutral

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
T2 Biosystems -563.16%N/A -174.06%

Acutus Medical has a beta of 5.68, suggesting that its stock price is 468% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.8, suggesting that its stock price is 680% more volatile than the broader market.

T2 Biosystems has higher revenue and earnings than Acutus Medical. T2 Biosystems is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Summary

T2 Biosystems beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to Minerva Surgical?

T2 Biosystems (NASDAQ:TTOO) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Minerva Surgical N/A N/A N/A

T2 Biosystems has a beta of 7.8, indicating that its stock price is 680% more volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market.

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

23.2% of T2 Biosystems shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 8.5% of Minerva Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, T2 Biosystems had 1 more articles in the media than Minerva Surgical. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for Minerva Surgical. T2 Biosystems' average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
Minerva Surgical Neutral

Summary

Minerva Surgical beats T2 Biosystems on 6 of the 10 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$8K$39.45M$6.52B$12.05B
Dividend YieldN/A1.08%2.67%5.66%
P/E Ratio0.0017.8224.0024.42
Price / Sales0.0027.38514.65112.54
Price / CashN/A18.8627.4837.92
Price / Book0.0012.2810.696.82
Net Income-$50.08M-$16.77M$3.57B$337.56M
7 Day PerformanceN/A1.07%0.61%1.16%
1 Month PerformanceN/A-5.05%1.56%3.16%
1 Year PerformanceN/A-9.38%25.44%30.60%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-99.7%$8K$7.68MN/A180
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
AFIB
Acutus Medical
N/A$0.00
-50.0%		N/AN/A$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel